Gene delivery and gene therapy with herpes simplex virus-based vectors

被引:40
|
作者
Latchman, DS [1 ]
机构
[1] UCL, Inst Child Hlth, London WC1N 1EH, England
关键词
gene delivery; gene therapy; virus vectors; Herpes simplex virus; neurological disease;
D O I
10.1016/S0378-1119(01)00322-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The development of efficient means of delivery genes in vivo is essential both for resting gene function in the intact animal and for human gene therapy procedures. A number of viral and non-viral gene delivery methods have been developed for this purpose. OF those herpes simplex virus (HSV)-based vectors have particular advantages for gene delivery to the nervous system including their ability to infect nondividing neurones and establish asymptomatic latent infections. Moreover, considerable progress has been made, firstly, in disabling HSV vectors so ns to prevent thr damaging effects of wild type virus and secondly, to ensure long-term expression of the inserted transgene(s). These vectors thus offer a valuable tool for testing gene function in neuronal cells in vivo and may ultimately be safe enough for use in human gene therapy procedures. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [31] Adeno-associated virus-based vectors and their application for gene therapy
    Serra, C
    Zentilin, L
    Giacca, M
    MINERVA BIOTECNOLOGICA, 1996, 8 (03) : 183 - 190
  • [32] Engineering herpes simplex virus vectors for gene transfer to neurons
    Fink, DJ
    Glorioso, JC
    NATURE MEDICINE, 1997, 3 (03) : 357 - 359
  • [33] Herpes simplex virus vectors for gene transfer to the nervous system
    Goins, WF
    Krisky, D
    Marconi, P
    Oligino, T
    Ramakrishnan, R
    Poliani, PL
    Fink, DJ
    Glorioso, JC
    JOURNAL OF NEUROVIROLOGY, 1997, 3 : S80 - S88
  • [34] Engineering herpes simplex virus vectors for gene transfer to neurons
    David J. Fink
    Joseph C. Giorioso
    Nature Medicine, 1997, 3 : 357 - 359
  • [35] DEVELOPMENT AND APPLICATION OF HERPES-SIMPLEX VIRUS VECTORS FOR HUMAN GENE-THERAPY
    GLORIOSO, JC
    DELUCA, NA
    FINK, DJ
    ANNUAL REVIEW OF MICROBIOLOGY, 1995, 49 : 675 - 710
  • [36] Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
    Lim, Filip
    Khalique, Hena
    Ventosa, Maria
    Baldo, Aline
    CURRENT GENE THERAPY, 2013, 13 (06) : 478 - 491
  • [37] THE USE OF HERPES-SIMPLEX VIRUS VECTORS FOR GENE-THERAPY IN NEUROLOGICAL DISEASES
    KENNEDY, PGE
    STEINER, I
    QUARTERLY JOURNAL OF MEDICINE, 1993, 86 (11): : 697 - 702
  • [38] Gene Therapy for Bladder Overactivity and Nociception with Herpes Simplex Virus Vectors Expressing Preproenkephalin
    Yokoyama, Hitoshi
    Sasaki, Katsumi
    Franks, Michael E.
    Goins, William F.
    Goss, James R.
    de Groat, William C.
    Glorioso, Joseph C.
    Chancellor, Michael B.
    Yoshimura, Naoki
    HUMAN GENE THERAPY, 2009, 20 (01) : 63 - 71
  • [39] Gene therapy for nephrogenic diabetes insipidus with virus-based vectors carrying aquaporin 2 gene
    Kondo, Taka-aki
    Nagasaki, Hiroshi
    Suga, Hidetaka
    Inoue, Makoto
    Hasegawa, Mamoru
    Oiso, Yutaka
    ENDOCRINE JOURNAL, 2010, 57 : S495 - S495
  • [40] Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders
    Kennedy, PGE
    BRAIN, 1997, 120 : 1245 - 1259